Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, has realigned its global business operations as part of a long-term strategic shift. As part of this realignment, Rentschler Biopharma will withdraw from the field of cell and gene therapy, ceasing operations at its Stevenage, UK site, and increase its focus on biologics. This decision is part of the company’s strategy to adapt to evolving market conditions and client needs, pr...